Triveni Bio

Triveni Bio is a private, clinical-stage biotech leveraging human genetics and antibody engineering to pioneer novel treatments for immune-mediated diseases. The company's strategy is built on three foundational pillars: a genetics-informed target discovery approach, advanced antibody engineering capabilities, and a focus on pioneering novel biology. Its most advanced asset, TRIV-509, has entered Phase 2 trials for atopic dermatitis, aiming to address a root cause of disease distinct from current Th2-focused therapies. The company was recognized as a 'Fierce 15' Biotech Company in 2025, indicating strong industry validation of its platform and approach.

An integrated platform combining a genetics-informed approach for target discovery, advanced antibody engineering, and a focus on pioneering novel biology to develop first-in-class therapeutics for immune and inflammatory diseases.

Triveni operates in the highly competitive atopic dermatitis market, dominated by biologics targeting IL-4/13 (dupilumab, lebrikizumab) and JAK inhibitors. Its strategy is to differentiate by targeting a novel, genetically-validated pathway outside the Th2 axis, aiming for efficacy in patients underserved by current standards of care.